Vaccine breakthrough stops cancer returning in trial

By Joe McFadden, Health reporter. Captured via firecrawl (full page). VERBATIM:

- Lead: "A new personalised vaccine given in combination with a drug has stopped skin cancer returning in patients during a trial, representing a potentially watershed moment in cancer treatment."
- "Early results show this new jab extended the length of time these patients were cancer free, but it's unclear for how long, according to an announcement by the two firms."
- "Cancer experts say this is a breakthrough, but emphasise caution as the full results have not been released or peer-reviewed whereby independent experts examine and check the trial findings."
- "The vaccine, called Intismeran, was given in combination with Keytruda, an immunotherapy drug already used in cancer treatment."
- "Compared with taking the Keytruda on its own, the companies said taking the drug and vaccine together significantly increased the time patients remained cancer free and reduced the risk of the disease spreading to other organs."
- "The phase three trial involved more than 1,000 patients who had high-risk stage two, three or four melanoma - meaning they ranged from having large tumours in a specific area to cancers which had already spread to other parts of the body."
- "Stephane Bancel, chief executive of Moderna, said the findings represent a "pivotal moment" in the field of cancer research."
- "Shares in both Moderna and Merck have surged since the announcement."
- Prof Peter Johnson, National Clinical Director for Cancer at NHS England, told the BBC's Today Programme: "Most of the cancer immune treatments we have been using up til now have been about cutting the immune system loose and hoping that it recognises the cancer. This \[new treatment\] is a way to direct it very specifically." "It feels like it's a very important advance for us."
- Dr Talisia Quallo, head of prevention and early detection at Cancer Research UK: the research "shows promise" but "the interim data still needs to be fully reviewed."
- Dr Lennard Lee, consultant medical oncologist, University of Oxford: "This is certainly good news for patients with melanoma, but the study has much wider implications. It provides proof of principle that personalised cancer vaccines work."
- "More detailed findings from the study will be presented at a medical conference in October."

AUDIT NOTE: RSS summary/ogDescription (load-bearing): "A new jab extended the length of time patients were cancer free, but it is unclear for how long." BBC frames the result with explicit uncertainty ("it's unclear for how long", "full results have not been released or peer-reviewed") and notes the NHS would still need a second approval process before availability.